Oncolytic virotherapy for hepatocellular carcinoma:A potent immunotherapeutic landscape  

作　　者：Rong Xiao Hao Jin Fang Huang Biao Huang Hui Wang Yi-Gang Wang 

机构地区：[1]College of Life Sciences and Medicine,Zhejiang Sci-Tech University,Hangzhou 310018,Zhejiang Province,China [2]Department of Pathology,Laboratory Medicine Center,Zhejiang Provincial Peoples’Hospital,Peoples’Hospital of Hangzhou Medical College,Hangzhou 310014,Zhejiang Province,China [3]Department of Oncology,Zhejiang Xiaoshan Hospital,Hangzhou 310018,Zhejiang Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第7期2867-2876,共10页世界胃肠肿瘤学杂志(英文)

基　　金：Supported by the Public Welfare Technology Project of Zhejiang Province,No.LGF21H160033;Zhejiang Medical Technology Plan Project,No.2021KY047;Hangzhou Medical Health Science and Technology Project,No.B20220173.

摘　　要：Hepatocellular carcinoma(HCC)is a systemic disease with augmented malignant degree,high mortality and poor prognosis.Since the establishment of the immune mechanism of tumor therapy,people have realized that immunotherapy is an effective means for improvement of HCC patient prognosis.Oncolytic virus is a novel immunotherapy drug,which kills tumor cells and exempts normal cells by directly lysing tumor and inducing anti-tumor immune response,and it has been extensively examined as an HCC therapy.This editorial discusses oncolytic viruses for the treatment of HCC,emphasizing viral immunotherapy strategies and clinical applications related to HCC.

关 键 词：Oncolytic virus Immunotherapeutic Hepatocellular carcinoma VIROTHERAPY EDITORIAL 

分 类 号：R735.7[医药卫生—肿瘤]